Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancers in a Multiethnic Malaysian Patient Population

Liam, Chong Kin; Leow, Alex Hwong Ruey; How, Soon-Hin; Pang, Yong‐Kek; Chua, Kek Heng; Lim, Boon-Khaw; Lai, Nai-Lang; Kuan, Yeh Chunn; Pailoor, Jayalakshmi; Rajadurai, Pathmanathan

doi:10.7314/apjcp.2014.15.1.321

Cited by 16 publications

(17 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EGFR TKIs are established as effective therapies in patients who have activating and sensitising mutations in exons 18-21 of [54]. A study in multi-ethnic Malaysian patients with NSCLC showed the prevalence of EGFR mutations (36.4%) to be similar [55]. Generally, female sex, adenocarcinoma histology, never-smoking status, and Asian ethnicity are considered the most important factors associated with EGFR mutation positive disease and response to EGFR-TKIs [54,56].…”

Section: Annals Of Oncologymentioning

confidence: 99%

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

et al. 2019

View full text Add to dashboard Cite

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of metastatic non-small-cell lung cancer (NSCLC) was published in 2016. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and the Chinese Society of Clinical Oncology (CSCO) to convene a special guidelines meeting immediately after the Chinese Thoracic Oncology Group Annual Meeting 2018, in Guangzhou, China. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic NSCLC cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic NSCLC representing the oncological societies of China (CSCO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the six participating Asian countries. During the review process, the updated ESMO 2018 Clinical Practice Guidelines for metastatic NSCLC were released and were also considered, during the final stages of the development of the Pan-Asian adapted Clinical Practice Guidelines.

show abstract

Section: Annals Of Oncologymentioning

confidence: 99%

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Epidermal growth factor receptor (EGFR) is a type of receptor tyrosine kinase, and it has been reported that EGFR mutations are mainly concentrated in exons 19 and 21 (Ji et al, 2006;Lim et al, 2014;Liam et al, 2014). After epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment, the signaling through Zhong-Ming Yang 1,2 , Xian-Ping Ding 1 *, Lei Pen 2 , Lin Mei 2 , Ting Liu 2 this pathway is blocked, leading to tumor cell necrosis.…”

Section: Introductionmentioning

confidence: 99%

Analysis of CEA Expression and EGFR Mutation Status in Non-small Cell Lung Cancers

Yang¹,

Ding²,

Pen³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The serum carcinoembryonic antigen (CEA) level can reflect tumor growth, recurrence and metastasis. It has been reported that epidermal growth factor receptor (EGFR) mutations in exons 19 and 21may have an important relationship with tumor cell sensitivity to EGFR -TKI therapy. In this study, we investigated the clinical value of EGFR mutations and serum CEA in patients with non-small cell lung cancer (NSCLC). Materials and Methods:The presence of mutations in EGFR exons 19 and 21 in the tissue samples of 315 patients with NSCLC was detected with real-time fluorescent PCR technology, while the serum CEA level in cases who had not yet undergone surgery, radiotherapy, chemotherapy and targeted therapy were assessed by electrochemical luminescence. Results: The mutation rates in EGFR exons 19 and 21 were 23.2% and 14.9%, respectively, with the two combined in 3.81%. Measured prior to the start of surgery, radiotherapy, chemotherapy and targeted treatment, serum CEA levels were abnormally high in 54.3% of the patients. In those with a serum CEA level <5 ng/mL, the EGFR mutation rate was 18.8%, while with 5~19 ng/mL and ≥20 ng/mL, the rates were 36.4% and 62.5%. In addition, in the cohort of patients with the CEA level being 20~49 ng/mL, the EGFR mutation rate was 85.7%, while in those with the CEA level ≥50 ng/mL, the EGFR mutation rate was only 20.0%, approximately the same as in cases with the CEA level<5 ng/mL. Conclusions: There is a positive correlation between serum CEA expression level and EGFR mutation status in NSCLC patients, namely the EGFR mutation-positive rate increases as the serum CEA expression level rises within a certain range (≥20 ng/mL, especially 20~49 ng/mL). If patient samples are not suitable for EGFR mutation testing, or cannot be obtained at all, testing serum CEA levels might be a simple and easy screening method. Hence, for the NSCLC patients with high serum CEA level (≥20 ng/mL, especially 20~49 ng/mL), it is worthy of attempting EGFR-TKI treatment, which may achieve better clinical efficacy and quality of life.

show abstract

“…The only EGFR-mutation-positive squamous cell carcinoma was from a never smoker whereas the squamous cell carcinomas from all 10 smokers were EGFR-mutation negative. 3 Other expert panels 4 recommend that apart from nonsquamous NSCLC, EGFR mutation testing should be performed in squamous cell carcinoma patients with clinical features associated with higher prevalence of EGFR mutations such as a lack of smoking history. Furthermore, adenosquamous carcinomas and solid adenocarcinomas, in which EGFR mutations have been reported, can mimic squamous cell carcinoma in small biopsy specimens.…”

Section: To the Editormentioning

confidence: 99%

“…2 The authors showed that the overall frequency of the EGFR mutation was 21%, which is higher than that in white population (11%-13.7%). [3][4][5][6] Mutations were mainly detected in the exon 19 (69%), followed by exon 21 (21%) and exon 20 (7%), whereas mutations in the…”

Section: To the Editormentioning

confidence: 99%

EGFR Mutation Testing for Squamous Cell Lung Carcinoma

Liam

Leow

Pang

2013

Journal of Thoracic Oncology

Self Cite

View full text Add to dashboard Cite

Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancers in a Multiethnic Malaysian Patient Population

Cited by 16 publications

References 43 publications

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

Analysis of CEA Expression and EGFR Mutation Status in Non-small Cell Lung Cancers

EGFR Mutation Testing for Squamous Cell Lung Carcinoma

Contact Info

Product

Resources

About